Close

ActivatorPep™ Zika NS1 (CA-LX106)

Online Inquiry  Datasheet

All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.

Specific Inquiry

  • Size:
  Add to Cart
  • Product Name
  • ActivatorPep™ Zika NS1
  • Cat. No.
  • CA-LX106
  • Product Summary
  • Creative Biolabs provides an extensive cell activation reagents including Expansion Kits and Activator peptides for global custom, which are suitable to many applications, such as in vitro stimulation antigen-specific cells. Zika NS1 is a pool of lyophilized peptides, consisting mainly of 15-mer sequences with 11 amino acids overlap, covering the sequence of the Zika non‑structural protein domain 1 (NS1) from virus isolate Z1106033 polyprotein gene (GenBank Acc. no. KU312312.1). Which can be used for in vitro stimulation of Zika NS1-specific T cells.
  • Background Information
  • The Zika non-structural protein domain 1 from virus isolate Z1106033 polyprotein gene comprises the amino acids 794-1146 of the full length polyprotein. The Zika virus belongs to the family of flaviviruses and is spread by Aedes mosquitos. In most cases no symptoms are observed after infection, but about 20% of Zika infected individuals react with symptoms like fever, red eyes, joint pain, and headache. During pregnancy the virus can spread to the fetus and cause microcephaly and other brain malformations. The virus is distributed in around 40 countries and the Aedes mosquitos can be found in all tropical and subtropical areas.
  • Applications
  • Stimulation Reagents
  • Cross-reactivity
  • No significant cross-reactivity was observed among analytes in this panel.
  • Species Reactivity
  • Human
  • Purity or Quality Grade
  • Research Grade
  • Downstream Application
  • Pulsing of antigen-presenting cells for research;
    Detection and analysis of antigen-specific CD4+ and CD8+ effector/memory T cells in PBMCs;
  • Product Size
  • for stimulation of 1×108 cells
  • Shipping Condition
  • The product is shipped with polar packs. Upon receipt, store it immediately at the temperature recommended below.
  • Storage Conditions
  • Store at -20°C.
  • Shelf life
  • > 6 Months from date of receipt under proper storage condition.
  • Product Use Statement
  • For research use only, not for diagnostic or therapeutic use.
  • Product Features
  • Efficient expansion and increased survival rate of Ag-specific T cells;
    Provides a gentle activation stimulus that maintains high viability of activated and expanded T cells;
  • Principle of the Assay
  • In vitro stimulation of antigen-specific T cells with Peptide Pools causes the secretion of effector cytokines and the up-regulation of activation markers, which then allow the detection and isolation of antigen-specific T cells.
  • Research Category
  • Immunology
  • Panel Type
  • Stimulation for CD4+ and CD8+ T cells

Customer Reviews and Q&As

There are currently no customer reviews or questions for ActivatorPep™ Zika NS1 (CA-LX106). Click the button below to contact us or submit your feedback about this product.

For research use only. Not intended for any clinical use. No products from Creative Biolabs may be resold, modified for resale or used to manufacture commercial products without prior written approval from Creative Biolabs.

Related Products

Online Inquiry

For any technical issues or product/service related questions, please leave your information below. Our team will contact you soon.

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Key Updates
Newsletter NEWSLETTER

The latest newsletter to introduce the latest breaking information, our site updates, field and other scientific news, important events, and insights from industry leaders

LEARN MORE NEWSLETTER
New Solution NEW SOLUTION

CellRapeutics™ In Vivo Cell Engineering: One-stop in vivo T/B/NK cell and macrophage engineering services covering vectors construction to function verification.

LEARN MORE SOLUTION
NOVEL SOLUTION NOVEL TECHNOLOGY

Silence™ CAR-T Cell: A novel platform to enhance CAR-T cell immunotherapy by combining RNAi technology to suppress genes that may impede CAR functionality.

LEARN MORE NOVEL TECHNOLOGY
NEW TECHNOLOGY NEW SOLUTION

Canine CAR-T Therapy Development: From early target discovery, CAR design and construction, cell culture, and transfection, to in vitro and in vivo function validation.

LEARN MORE SOLUTION
Receive our latest news and insights.